Bishop Hans Edgar 4

What Happened

• Bishop Hans Edgar, a director of Sana Biotechnology, was granted a derivative award on 2026-06-04 covering 90,000 shares. The transaction is reported with a per‑share amount of $0.00 (reported value $0), indicating an option-style award rather than an open‑market purchase. The option vests 100% on the earlier of June 4, 2027 or immediately prior to Sana’s 2027 annual meeting, subject to continued service.

Key Details

• Transaction date: 2026-06-04; Form filed: 2026-06-05 (timely filing the next day).
• Transaction type: Derivative award (option grant) — 90,000 shares; reported price: $0.00.
• Vesting: 100% vests on earlier of June 4, 2027 or immediately prior to the 2027 annual meeting, contingent on continued service (per footnote).
• Shares owned after transaction: not specified in the public Form 4 filing.
• No exercise or sale occurred — this is a grant of an option/award, not an immediate purchase or disposition.

Context

• This was an award of a future right to acquire shares (an option), not an immediate open‑market buy. Such grants are common for directors as compensation and do not by themselves indicate a near‑term purchase or sale. The reported $0.00 value reflects the filing format and vesting/exercise mechanics, not a market valuation of the potential future shares.